Introduction
============

Approximately 50% or more patients with cancer develop bone metastasis, and this is more common in patients with breast, prostate, and lung cancers.[@b1-jpr-9-859],[@b2-jpr-9-859] Bone metastasis often involves the vertebral column, pelvis, ribs, and proximal femur, whereas distal femur metastases are rare. The most frequent symptom is intense and drug-resistant pain that produces alterations in mobility and adversely and remarkably impacts the patient's quality of remaining life.

Currently, therapies for such patients include surgery, radiation therapy, chemotherapy, targeted therapy, immune therapy, and the use of bisphosphonates.[@b3-jpr-9-859]--[@b7-jpr-9-859] However, pharmacological handling is insufficient to control pain, regain immediate bone integrity, and allow early weight bearing. Surgical intervention may be limited owing to high rates of complications and comorbidities.[@b8-jpr-9-859] Therefore, a technique that can immediately restore the mechanical stability of the affected bones and allow immediate weight bearing is especially important.[@b9-jpr-9-859],[@b10-jpr-9-859]

Fortunately, percutaneous cementoplasty, a new and minimally invasive technique, has been proven to be an effective therapy for bone metastatic lesions in the spine, pelvis, ilium, and proximal femur.[@b9-jpr-9-859]--[@b15-jpr-9-859] It can alleviate pain [@b9-jpr-9-859],[@b10-jpr-9-859] and reduce metastatic activity[@b16-jpr-9-859] while simultaneously offering stability to the affected bones.[@b13-jpr-9-859]--[@b15-jpr-9-859] However, to the best of our knowledge, there has been no report thus far that addresses percutaneous cementoplasty for distal femur metastasis. Therefore, in this paper, we investigated the clinical benefits of this technique in distal femur metastasis with respect to pain relief, mobility improvement, and improved quality of life.

Case report
===========

A 58-year-old woman who was diagnosed with non-small-cell lung cancer (stage IV) in March 2015 was referred in October 2015 to our department by her oncologist for severe knee pain and inability to ambulate. When the patient was initially diagnosed with lung cancer, opposite lung metastasis and rib metastasis had already occurred. The primary cancer was controlled with systematic chemotherapy. She described her knee pain as being 8 out of 10 on the visual analog scale (VAS), and her pain was drug resistant. Oxycodone hydrochloride prolonged-release tablets were administered at a dosage of 100 mg/12 h, but there was no significant pain relief. Zoledronic acid was administrated at a dosage of 4 mg/4 wk, and her renal function was monitored. On physical examination, her left knee was grossly swollen, with generalized tenderness of the distal femur bone. Extension movements of her left knee would produce serious pain, and she was unable to stand or bear weight unaided. Radiography ([Figure 1](#f1-jpr-9-859){ref-type="fig"}) confirmed the lytic destruction of the distal femur bone. Computed tomography showed the extent of the bone destruction, and magnetic resonance imaging showed the extent of the metastatic lesion ([Figure 2](#f2-jpr-9-859){ref-type="fig"}). The patient did not have operative contraindications, such as local infection at the operation site, abnormal coagulation, and platelet dysfunction; hence, she was offered palliative radiotherapy, total knee arthroplasty, or an attempt at restoration by percutaneous cementoplasty as treatment choices. She chose to undergo restoration incorporating polymethylmethacrylate cementoplasty.

This study was approved by the Medical Research Ethics Board of the Affiliated Hospital of Academy of Military Medical Sciences, and informed consent was obtained prior to performing all procedures. Written informed consent was obtained for publication of this paper and the accompanying images.

The patient was placed in the supine position. The patient's blood pressure, pulse, PaO~2~, and electrocardiogram were continuously monitored during the surgery. The operation site was infiltrated with 2% lidocaine + ropivacaine + normal saline (1.5:1:2). Under fluoroscopic guidance, a single 13-gauge needle was advanced into the metastatic lesion. Subsequently, we obtained metastatic tissues using a bone biopsy needle, and then injected the cement (approximately 6 mL) through the 13-gauge needle under real-time fluoroscopic guidance. The filling was stopped when the distribution of cement in the metastatic lesion had been achieved. No complications occurred during the procedure.

We used the VAS, with scores ranging from 0 (indicating no pain) to 10 (indicating the greatest imaginable pain), to assess pain outcome. When the VAS score improved by three points or more, the procedure was considered effective.[@b11-jpr-9-859] Mobility was assessed with the mobility scale, wherein a score of 1 represented no limitation, 2 represented limitation without the need for orthopedic aids, 3 represented limitation necessitating orthopedic aids, and 4 represented bedridden operative technique.[@b17-jpr-9-859] Both the VAS and mobility scales were applied 24 hours before and after the procedure and at 1, 2, and 4 weeks and at 3 months after the procedure. The clinical complications that occurred during the procedure or within 24 hours after the procedure were documented in the report.

Results
=======

Under local anesthetic, the patient was treated with percutaneous cementoplasty. No complications were observed during the operation and within 24 hours postoperatively. Her pain dropped from a preoperative VAS score of 8--6 within 24 hours postoperatively. Following surgery, analgesic drugs were administrated at a dosage of 10 mg/12 h. Postoperative radiography showed cementation ([Figure 3](#f3-jpr-9-859){ref-type="fig"}). The distal femur lesion was treated by regional radiotherapy 3 days after surgery. A bone biopsy 5 days after surgery confirmed metastasis resulting from lung adenocarcinoma. The patient was discharged from the hospital 1 week after the operation. At that time, she was non-weight-bearing and was able to move only with the use of a walker. One week after the operation, she described her pain as 3 out of 10 on the VAS. At the second week follow-up visit, the sutures were removed and full weight bearing was possible. Her VAS-based pain score remained steady at 3 out of 10. At 4 weeks, her mobility had increased and she was able to walk across a corridor and go up and down the stairs without a walker. Meanwhile, the pain score further dropped from 3 to 2. Details of VAS and mobility scales are shown in [Figure 4](#f4-jpr-9-859){ref-type="fig"}.

Discussion
==========

The aim of treatment in patients with bone metastasis is to reduce pain, to maintain mobility, and to positively improve the patient's quality of remaining life. Currently, the therapies for these patients include surgery, radiation therapy, chemotherapy, targeted therapy, immune therapy, and the use of bisphosphonates.[@b3-jpr-9-859],[@b4-jpr-9-859] However, pharmacological handling is insufficient to control pain, immediately regain bone integrity, and allow early weight bearing. Surgical intervention may be limited on account of high rates of complication and comorbidities.[@b8-jpr-9-859] Therefore, a treatment method that can provide pain control and improve bone stability at the same time is necessary.

Percutaneous cementoplasty can immediately restore the mechanical stability of the affected bone, prevent further risk of bone fractures, and allow immediate weight bearing. Therefore, it is emerging as one of the most promising procedures for patients with painful bone metastasis who are unsuitable for surgery or who show resistance to radiotherapy and/or analgesic treatment.[@b9-jpr-9-859] Previous studies reported that 60%--84% of patients with metastatic compression fracture experienced marked or complete pain relief after vertebroplasty.[@b10-jpr-9-859],[@b11-jpr-9-859] In a multicenter randomized controlled trial, as compared with the nonsurgical group, the kyphoplasty group showed improved functional outcomes for patients with painful metastatic compression fracture, based on the Roland Morris disability questionnaire scores.[@b12-jpr-9-859]

Regarding femoral metastasis, Plancarte et al[@b13-jpr-9-859] reported that all patients achieved pain reduction on the treated pelvic member, along with improved mobility, after femoroplasty in a series of 15 patients with bone metastases located in the head, neck, and proximal femur. In a larger population, Plancarte et al[@b14-jpr-9-859] also showed that all 80 patients had a decrease in the intensity of pain, reduced analgesic consumption, and improved quality of life at 7 and 30 days after the intervention, and there were no serious complications. In a systematic review of long bone tumors treated with percutaneous cementoplasty compiled by screening 1,598 articles and covering 196 patients, Cazzato et al[@b15-jpr-9-859] found that 27.4%--68.2% patients showed pain improvement and 6%--71.9% patients obtained functional improvement. Cazzato et al[@b18-jpr-9-859] also demonstrated in a series of 51 patients that percutaneous long bone cementoplasty was a safe and effective option. Local pain relief was observed in 89.4% lesions, and limb functionality was improved in 71.8% lesions. However, percutaneous cementoplasty in long bone is controversial. The primary argument has been that injecting cement directly into osteolytic lesions cannot provide adequate mechanical stability for long bones, which are considered to be very resistant to compressive forces but less resistant to torsional forces.[@b19-jpr-9-859]--[@b21-jpr-9-859] Liu et al[@b22-jpr-9-859] concluded that the efficacy of percutaneous long bone cementoplasty through embedding a cement-filled catheter in the medullary canal for painful long bone metastases with impending fracture was superior to percutaneous long bone cementoplasty alone in terms of pain relief, functional improvement, and the rate of fractures of the treated long bone. Deschamps et al[@b23-jpr-9-859] also showed that percutaneous osteosynthesis plus cementoplasty was a promising method in the treatment of impending pathological fracture of the proximal femur. Overall, the combination of cementoplasty with other techniques produced encouraging results, but further investigations are still required for confirmation.

It has been suggested that when the polymethylmethacrylate bone cement is injected, it reconstructs stabilization of the destroyed bone and the microfracture, and the thermal action produced by the cement probably reduces the metastatic activity and inhibits the regional nociceptors, thus alleviating pain.[@b16-jpr-9-859] In the present study, our patient was treated with percutaneous cementoplasty. No complications were observed during the operation and 24 hours postsurgery. Her pain decreased from a preoperative VAS score of 8 to 4 within 24 hours of the procedure. She was discharged from hospital 1 week after the operation. At that time, she was non-weight-bearing and used a walker for mobility; she described her postoperative pain score as 2 out of 10. At the 2-week follow-up visit, full weight bearing was possible. At 4 weeks, her mobility had increased and she was able to go up and down stairs without using the walker. It is important to note that the patient's vital signs were continuously monitored during the procedure when we injected the cement so as to prevent related complications of cement leaking into the vessel.

Conclusion
==========

In conclusion, percutaneous cementoplasty for osteolytic distal femur metastases is a relatively safe option, offering acceptable pain relief and restoring impaired knee function. We believe that this minimally invasive procedure is most suitable for patients having pain due to distal femur metastasis, thereby presenting a high risk of fractures of the involved femoral bone, or those with rapidly deteriorating quality of life. Nevertheless, for further confirmation, larger samples and retrospective or prospective studies are warranted.
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![**(A)** Posteroanterior radiograph; **(B)** lateral radiograph confirming lytic destruction of the distal femur bone.](jpr-9-859Fig1){#f1-jpr-9-859}

![**(A and B)** CT shows the extent of bone destruction; **(C and D)** MRI shows the extent of the metastatic lesion.\
**Abbreviations:** CT, computed tomography; MRI, magnetic resonance imaging.](jpr-9-859Fig2){#f2-jpr-9-859}

![**(A)** Posteroanterior radiograph; **(B)** lateral radiograph showing the distribution of cement after percutaneous cementoplasty.](jpr-9-859Fig3){#f3-jpr-9-859}

![VAS and mobility scores before and after the procedure.\
**Abbreviation:** VAS, visual analog scale.](jpr-9-859Fig4){#f4-jpr-9-859}
